What is Fertilis?
Based in Adelaide, South Australia, Fertilis operates at the intersection of medical device manufacturing and reproductive biology. The company has developed a sophisticated IVF platform that automates the cultivation process by housing each embryo within a patented micro-3D printed pod. This technological framework provides a controlled, protective environment that allows for precise, automated adjustments to the nutritive solutions surrounding the embryo. By replacing manual, labor-intensive laboratory procedures with high-precision automation, Fertilis aims to improve clinical outcomes and standardize the quality of care in fertility clinics globally. The firm's focus on micro-scale environmental control represents a significant shift toward precision medicine in the fertility sector, positioning it as a key player in the evolution of assisted reproductive technologies.
How much funding has Fertilis raised?
Fertilis has raised a total of $2.5M across 1 funding round:
Angel/Seed
$2.5M
Angel/Seed (2022): $2.5M with participation from Horizons Ventures
Key Investors in Fertilis
Horizons Ventures
Horizons Ventures focuses on investing in deep science and technology aimed at advancing humanity towards a significantly improved future. The company seeks to support innovative projects that have the potential to create transformative changes.
What's next for Fertilis?
With this major strategic investment, Fertilis is expected to accelerate its research and development initiatives, focusing on the commercialization of its micro-3D printed pod technology. The company will likely prioritize expanding its clinical validation studies and navigating the regulatory pathways necessary for broader market adoption. As the firm transitions from its initial development phase into a scaling enterprise, the focus will shift toward establishing manufacturing partnerships and integrating its automated systems into existing IVF laboratory workflows. This capital infusion provides the necessary runway to refine its nutritive composition delivery systems and solidify its intellectual property portfolio, ensuring a competitive advantage in the rapidly evolving global fertility market.
See full Fertilis company page
